Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.
Okamoto H, Inoue Y, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida SI, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J; KOTOSG investigators.
Okamoto H, et al. Among authors: chinen s.
Int J Hematol. 2023 Sep;118(3):323-332. doi: 10.1007/s12185-023-03627-6. Epub 2023 Jun 28.
Int J Hematol. 2023.
PMID: 37378717